Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or
Faster, Cleaner, Better.

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
0.9200 -0.0199 (-2.12%) 07/03/25 [NASDAQ]
0.9019 x 1,000 0.9398 x 11,600
Realtime by (Cboe BZX)
0.9019 x 1,000 0.9398 x 11,600
Realtime 0.9398 +0.0198 (-) 07/03/25
News & Headlines for Thu, Jul 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar

CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncology at Piedmont Atlanta Hospital and founding physician...

CNSP : 0.9200 (-2.12%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery...

CNSP : 0.9200 (-2.12%)
BMWYY : 29.2000 (+4.58%)
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer

CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial....

CNSP : 0.9200 (-2.12%)
BMWYY : 29.2000 (+4.58%)
CNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on brain and central nervous system cancers, has priced a “reasonable best efforts” public offering with a single healthcare-focused...

CNSP : 0.9200 (-2.12%)
BMWYY : 29.2000 (+4.58%)
CNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive...

CNSP : 0.9200 (-2.12%)
BMWYY : 29.2000 (+4.58%)
CNS Pharmaceuticals (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D...

CNSP : 0.9200 (-2.12%)
CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Company has one year of cash to fund operations

CNSP : 0.9200 (-2.12%)
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary...

CNSP : 0.9200 (-2.12%)
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.

CNSP : 0.9200 (-2.12%)
CNS Pharmaceuticals (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company focused on treatments for brain and central nervous system cancers, provided an update on its cash position and efforts to maintain its Nasdaq...

CNSP : 0.9200 (-2.12%)

Barchart Exclusives

OpenAI’s Partnership With Microsoft is Good, Says CEO Sam Altman; There’s ‘Tension,’ But Already Planning ‘Next Decade Together’
Sam Altman’s collaborative leadership with Microsoft reflects his pragmatic approach to partnerships and his influence on the direction of artificial intelligence. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar